default title

A recent comprehensive literature review sought to determine if the specific day of the week chosen for administering once-weekly GLP-1 receptor agonists, including semaglutide and tirzepatide, influences key therapeutic outcomes. The study delved into various aspects, such as glucose regulation, reductions in body weight, patient adherence to treatment regimens, and the occurrence of adverse effects in individuals grappling with type 2 diabetes or obesity. Despite the increasing adoption of these medications, the available research did not conclusively identify an optimal day for administration, underscoring the potential importance of flexible, patient-centric dosing strategies.

Type 2 diabetes and obesity represent significant global health challenges, impacting millions worldwide. The advent of once-weekly injectable therapies like semaglutide, a GLP-1 receptor agonist, and tirzepatide, which acts as a dual GIP and GLP-1 receptor agonist, has revolutionized treatment approaches for these conditions. These medications boast extended half-lives, facilitating consistent drug exposure between doses. However, common side effects, such as nausea, can pose challenges to treatment adherence. While patients often choose their injection days based on personal convenience, there has been a notable lack of direct empirical evidence to guide the selection of the most advantageous day. This gap in knowledge highlights a critical need for further investigation into how administration timing might influence clinical effectiveness and patient experience.

The systematic literature review was meticulously conducted in accordance with the PRISMA 2020 guidelines, employing a PICO framework to structure the investigation. The study population encompassed adults aged 18 and older diagnosed with type 2 diabetes mellitus or classified as obese/overweight. Interventions under consideration included both subcutaneous and oral formulations of semaglutide or tirzepatide, with a focus on studies that explored specific dosing days, patient preferences, or flexible administration schedules. Primary outcomes assessed included glycated hemoglobin (HbA1c) levels, fasting plasma glucose, time-in-range (TIR), changes in body weight, weight loss percentages, treatment adherence and persistence, reported adverse events, and various patient-reported outcomes. The research team systematically searched several prominent databases, including SciSpace Deep Search, SciSpace Basic Search, SciSpace Full Text Search, Google Scholar, and PubMed, up to June 15, 2026. Initially, 1,471 records were identified, which were then rigorously screened in two stages using predefined PICO-based criteria. An AI-assisted scoring system was utilized during the abstract screening phase, with records achieving a score of at least 4.0 advancing to full-text assessment, where a stricter threshold of 4.5 was applied. Data extraction focused on study design, participant demographics, intervention timing, outcome measures, compliance data, and adverse effects. Methodological quality was evaluated using established tools such as the Cochrane Risk of Bias tool (RoB 2.0), the Newcastle-Ottawa Scale (NOS), and the Appraisal of Guidelines for Research and Evaluation II (AGREE II). It is important to note that the review protocol was not prospectively registered, and the AI-assisted screening process, due to proprietary algorithmic parameters, was not fully reproducible by independent reviewers.

Out of the initial 1,471 records, 380 duplicates were removed, and 91 records were trimmed to meet the screening target. Subsequently, 1,000 records underwent abstract screening, leading to the exclusion of 997 studies. The majority of exclusions (850) were due to a lack of focus on administration timing or day-of-week effects, while 100 studies assessed general efficacy without temporal analysis, and 47 concentrated on other GLP-1 RAs. Ultimately, only three studies satisfied the full-text assessment criteria and were included in the qualitative synthesis. These comprised one randomized controlled trial (RCT), one retrospective case series, and one expert panel discussion. None of these studies were specifically designed to directly compare different administration days for semaglutide or tirzepatide.

The SUSTAIN 4 investigation, a 30-week, open-label, parallel-group, multicenter, international phase 3a trial, involved 1,089 patients with type 2 diabetes whose condition was inadequately managed with metformin, either alone or in combination with sulfonylureas. Participants in this trial received weekly subcutaneous injections of semaglutide at doses of 0.5 or 1 mg, or daily injections of insulin glargine. The results indicated that semaglutide led to more significant reductions in HbA1c and body weight compared to insulin glargine. Specifically, for the 1.0-mg dose, the estimated treatment difference showed a -1.21 percentage point reduction for HbA1c and a -5.94 kg reduction in body weight. However, patients were allowed to choose their injection day based on personal preference, and the outcomes were not subsequently analyzed with respect to the chosen injection day. Therefore, while this trial affirmed the efficacy of semaglutide, it did not provide insights into whether a particular day of the week offered superior benefits.

A second study included in the review was a retrospective case series involving 10 adults with type 2 diabetes who were prescribed oral semaglutide at a 14 mg dose on an alternate-day regimen, primarily to mitigate gastrointestinal side effects. Analysis of ambulatory glucose profiles revealed no statistically significant differences in time-in-range (TIR), time-above-range (TAR), or time-below-range (TBR) between days when the medication was taken and days when it was omitted. These findings imply that the glucose-lowering effects of semaglutide might extend beyond the immediate post-dose period. Nevertheless, the small sample size of this study, its use of an unapproved alternate-day dosing regimen, the absence of a control group, and the inherent limitations of a case series significantly restrict the generalizability and causal interpretability of its conclusions.

The third piece of evidence considered was an expert panel discussion concerning flexible timing for oral semaglutide administration within Italian clinical practice. Drawing on expert opinions and limited observational data, the panel suggested that a flexible dosing schedule could potentially enhance adherence without compromising glycemic control or weight loss outcomes. They emphasized the importance of tailoring administration schedules to individual patient preferences, lifestyle, and tolerability. However, the discussion did not include any quantitative measurements of adherence or patient satisfaction. Consequently, the review categorized these conclusions as hypothesis-generating expert consensus rather than robust, evidence-based clinical recommendations.

The current body of evidence does not provide a definitive answer regarding an optimal day for administering semaglutide or tirzepatide to adults with type 2 diabetes or obesity. However, this absence of conclusive evidence should not be mistakenly interpreted as an indication that all dosing days are clinically equivalent. The limited number of studies, particularly those directly comparing different weekdays for drug administration, and the complete lack of research on tirzepatide administration timing, highlight significant gaps. Despite these limitations, preliminary indirect evidence and expert consensus suggest that flexible dosing schedules, carefully adapted to individual patient preferences and lifestyles, could potentially improve adherence and tolerability without negatively impacting glycemic control or weight management. Healthcare providers should therefore engage in shared decision-making with patients when determining an administration day, emphasizing the importance of consistent weekly dosing to achieve the best possible therapeutic outcomes.